Advertisement
Advertisement
GRCE
Grace Therapeutics, Inc. Common Stock
4.69
USDSponsored
+0.27
+5.99%
Mar 25, 16:00 UTC -4
Closed
Pre-Market
4.80
+0.11
+2.30%
GRCE Earnings Reports
Positive Surprise Ratio
GRCE beat 15 of 23 last estimates.
65%
Next Report
Date of Next Report
Jun 26, 2026
Estimate for Q4 26 (Revenue/ EPS)
--
/-$0.24
Implied change from Q3 26 (Revenue/ EPS)
--
/+71.43%
Implied change from Q4 25 (Revenue/ EPS)
--
/-340.00%
Grace Therapeutics, Inc. Common Stock earnings per share and revenue
On Feb 12, 2026, GRCE reported earnings of -0.14 USD per share (EPS) for Q3 26, beating the estimate of -0.28 USD, resulting in a 50.98% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.67% price change (close before vs. close after earnings).
Looking ahead to Q4 26, 4 analysts forecast an EPS of -0.24 USD, with revenue projected to reach -- USD, implying an increase of 71.43% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
MaxCyte, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
FAQ
What were Grace Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Grace Therapeutics, Inc. Common Stock reported EPS of -$0.14, beating estimates by 50.98%, and revenue of $0.00, 0% as expectations.
How did the market react to Grace Therapeutics, Inc. Common Stock's Q3 2026 earnings?
The stock price moved down -1.67%, changed from $3.59 before the earnings release to $3.53 the day after.
When is Grace Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Jun 26, 2026.
What are the forecasts for Grace Therapeutics, Inc. Common Stock's next earnings report?
Based on 4
analysts, Grace Therapeutics, Inc. Common Stock is expected to report EPS of -$0.24 and revenue of -- for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement